Cargando…

Sacubitril/Valsartan in the Treatment of Resistant Hypertension: Raising Star or Illusion?

Detalles Bibliográficos
Autores principales:	Tadic, Marijana, Cuspidi, Cesare
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181008/ https://www.ncbi.nlm.nih.gov/pubmed/35683468 http://dx.doi.org/10.3390/jcm11113081

Ejemplares similares

Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021)

Resistant hypertension and COVID-19: tip of the iceberg?
por: Tadic, Marijana, et al.
Publicado: (2021)

Can myocardial work help in the therapy of resistant hypertension?
por: Tadic, Marijana, et al.
Publicado: (2022)

Eligibility and Usage of Sacubitril/Valsartan in Korea
por: Kim, Jin-Jin, et al.
Publicado: (2019)

Left ventricular hypertrophy in hypertension: Need of ethnic‐specific criteria
por: Cuspidi, Cesare, et al.
Publicado: (2022)

Right Ventricle in Arterial Hypertension: Did We Forget Something?
por: Tadic, Marijana, et al.
Publicado: (2022)

How does trastuzumab treatment affect the right ventricle in females with breast cancer?
por: Tadic, Marijana, et al.
Publicado: (2015)

When sweet becomes too sweet: Left ventricular longitudinal strain in focus
por: Tadic, Marijana, et al.
Publicado: (2018)

Type 1 diabetes mellitus and atrial function: A complex relationship
por: Tadic, Marijana, et al.
Publicado: (2016)

Is there any relationship between cardiopulmonary capacity and cardiovascular mechanics in coronary artery disease?
por: Tadic, Marijana, et al.
Publicado: (2016)

Hypertensive and cognitive function: did we come to a dead end?
por: Tadic, Marijana, et al.
Publicado: (2022)

Hypertension, diastolic stress test, and HFpEF: Does new scoring system change something?
por: Tadic, Marijana, et al.
Publicado: (2019)

The influence of diabetes and hypertension on outcome in COVID‐19 patients: Do we mix apples and oranges?
por: Tadic, Marijana, et al.
Publicado: (2020)

COVID‐19, hypertension, and renin‐angiotensin‐aldosterone system inhibitors: Much ado about nothing or real problem to be solved?
por: Tadic, Marijana, et al.
Publicado: (2020)

Network meta-analysis of sacubitril/valsartan for the treatment of essential hypertension
por: Zhang, Yaling, et al.
Publicado: (2022)

White-Coat Hypertension: the Neglected Subgroup in Hypertension
por: Cuspidi, Cesare, et al.
Publicado: (2018)

Effects of Sacubitril/Valsartan on resistant hypertension and myocardial work in hemodialysis patients
por: Wang, Bin, et al.
Publicado: (2022)

Left ventricular hypertrophy in hypertension: Is the electrocardiogram enough for risk stratification?
por: Cuspidi, Cesare, et al.
Publicado: (2022)

Blood pressure variability and target organ damage regression in hypertension
por: Cuspidi, Cesare, et al.
Publicado: (2021)

Hypertension and cognitive dysfunction in elderly: blood pressure management for this global burden
por: Tadic, Marijana, et al.
Publicado: (2016)

Effects of Sacubitril/Valsartan on the Renal Resistance Index
por: Gioia, Margherita Ilaria, et al.
Publicado: (2022)

Effect of sacubitril/valsartan or valsartan on ventricular remodeling and myocardial fibrosis in perimenopausal women with hypertension
por: Chen, Jianshu, et al.
Publicado: (2023)

COVID‐19 and arterial hypertension: Hypothesis or evidence?
por: Tadic, Marijana, et al.
Publicado: (2020)

Targeting White Coat Hypertension: Is the Daytime Enough?
por: Cuspidi, Cesare, et al.
Publicado: (2020)

Clinical observation of sacubitril valsartan sodium in the treatment of resistant hypertension: A randomized clinical trial
por: Lyu, Tian-Jiao, et al.
Publicado: (2022)

The efficacy and safety of Sacubitril/Valsartan on pulmonary hypertension in hemodialysis patients
por: Zhao, Cong, et al.
Publicado: (2022)

The effects of sacubitril/valsartan and ramipril on the male fertility in hypertensive rats
por: Aykan, Duygun Altintas, et al.
Publicado: (2020)

The emerging role of sacubitril/valsartan in pulmonary hypertension with heart failure
por: Xu, Yu, et al.
Publicado: (2023)

Isolated Nocturnal Hypertension: What Do We Know and What Can We Do?
por: Tadic, Marijana, et al.
Publicado: (2020)

ECG Monitoring of Reactions to Sacubitril-valsartan in Heart Failure with Reduced Ejection Fraction
por: Kang, Min-Kyung
Publicado: (2020)

Implication of low dose sacubitril/valsartan
por: Imamura, Teruhiko
Publicado: (2021)

Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction
por: Jackson, Alice M, et al.
Publicado: (2021)

Is myocardial work the piece of puzzle that we missed?
por: Tadic, Marijana, et al.
Publicado: (2022)

Obstructive sleep apnea and left ventricular strain: Useful tool or fancy gadget?
por: Cuspidi, Cesare, et al.
Publicado: (2019)

Obstructive Sleep Apnea and Right Ventricular Remodeling: Do We Have All the Answers?
por: Tadic, Marijana, et al.
Publicado: (2023)

Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment
por: Anderson, Sarah L, et al.
Publicado: (2018)

Sacubitril/valsartan in the treatment of systemic right ventricular failure
por: Zandstra, Tjitske E, et al.
Publicado: (2021)

Sacubitril/valsartan in HFrEF – Should the aces up our sleeves be played earlier?
por: Boehmer, Andreas A., et al.
Publicado: (2019)

Hypertension and COVID-19: Ongoing Controversies
por: Tadic, Marijana, et al.
Publicado: (2021)

Effects of Sacubitril/Valsartan on Glycemic Control in Japanese Patients With Heart Failure and/or Hypertension
por: Sazawa, Kahomi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h3ciug7qqa4cjd1t8i8mnr51v9